Rexahn Pharmaceuticals, Inc. (RNN) Short Interest Update
Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was the target of a large drop in short interest during the month of September. As of September 15th, there was short interest totalling 752,788 shares, a drop of 2.7% from the August 31st total of 773,594 shares. Based on an average trading volume of 859,779 shares, the short-interest ratio is currently 0.9 days. Approximately 0.4% of the company’s shares are short sold.
Separately, Zacks Investment Research lowered shares of Rexahn Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, June 11th.
Shares of Rexahn Pharmaceuticals (NYSE:RNN) opened at 0.21 on Friday. The stock’s 50 day moving average is $0.24 and its 200-day moving average is $0.28. Rexahn Pharmaceuticals has a 52 week low of $0.20 and a 52 week high of $0.52. The company’s market cap is $44.79 million.
Rexahn Pharmaceuticals (NYSE:RNN) last issued its earnings results on Monday, August 8th. The company reported ($0.01) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.02) by $0.01. On average, equities analysts anticipate that Rexahn Pharmaceuticals will post ($0.07) earnings per share for the current year.
A hedge fund recently raised its stake in Rexahn Pharmaceuticals stock. Vanguard Group Inc. raised its stake in shares of Rexahn Pharmaceuticals, Inc. (NYSE:RNN) by 1.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,904,097 shares of the company’s stock after buying an additional 49,761 shares during the period. Vanguard Group Inc. owned 2.30% of Rexahn Pharmaceuticals worth $1,232,000 at the end of the most recent reporting period.
About Rexahn Pharmaceuticals
Rexahn Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company’s clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance.
Receive News & Stock Ratings for Rexahn Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rexahn Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.